LGND Quote, Financials, Valuation and Earnings

Elanco Animal Health, Inc. has a net margin of 75.06% compared to Ligand Pharmaceuticals, Inc.'s net margin of -24.13%. Ligand Pharmaceuticals, Inc.'s return on equity of 14.07% beat Elanco Animal Health, Inc.'s return on equity of -3.57%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $244.56, signalling upside risk potential of 20.74%. On the other hand Elanco Animal Health, Inc. has an analysts' consensus of $28.77 which suggests that it could grow by 10.27%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Elanco Animal Health, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Elanco Animal Health, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.207, which suggesting that the stock is 20.687% more volatile than S&P 500. In comparison Elanco Animal Health, Inc. has a beta of 1.833, suggesting its more volatile than the S&P 500 by 83.348%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elanco Animal Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Elanco Animal Health, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $59.7M, which are smaller than Elanco Animal Health, Inc. quarterly revenues of $1.1B. Ligand Pharmaceuticals, Inc.'s net income of $44.8M is higher than Elanco Animal Health, Inc.'s net income of -$276M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 34.71x while Elanco Animal Health, Inc.'s PE ratio is 339.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.28x versus 2.76x for Elanco Animal Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of 75.06% compared to Ligand Pharmaceuticals, Inc.'s net margin of -112.81%. Ligand Pharmaceuticals, Inc.'s return on equity of 14.07% beat Ionis Pharmaceuticals, Inc.'s return on equity of -67.97%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $244.56, signalling upside risk potential of 20.74%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $93.81 which suggests that it could grow by 14.46%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.207, which suggesting that the stock is 20.687% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.315, suggesting its less volatile than the S&P 500 by 68.536%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals, Inc. quarterly revenues are $59.7M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $203M. Ligand Pharmaceuticals, Inc.'s net income of $44.8M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$229M. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 34.71x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.28x versus 14.40x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 75.06% compared to Ligand Pharmaceuticals, Inc.'s net margin of 20.83%. Ligand Pharmaceuticals, Inc.'s return on equity of 14.07% beat Johnson & Johnson's return on equity of 34.46%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $244.56, signalling upside risk potential of 20.74%. On the other hand Johnson & Johnson has an analysts' consensus of $233.13 which suggests that it could fall by -6.21%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Ligand Pharmaceuticals, Inc. has a beta of 1.207, which suggesting that the stock is 20.687% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.338, suggesting its less volatile than the S&P 500 by 66.17%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.09% to investors and pays a quarterly dividend of $1.30 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals, Inc. quarterly revenues are $59.7M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Ligand Pharmaceuticals, Inc.'s net income of $44.8M is lower than Johnson & Johnson's net income of $5.1B. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 34.71x while Johnson & Johnson's PE ratio is 22.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.28x versus 6.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 75.06% compared to Ligand Pharmaceuticals, Inc.'s net margin of 18.15%. Ligand Pharmaceuticals, Inc.'s return on equity of 14.07% beat Merck & Co., Inc.'s return on equity of 36.76%.

Ligand Pharmaceuticals, Inc. has a consensus price target of $244.56, signalling upside risk potential of 20.74%. On the other hand Merck & Co., Inc. has an analysts' consensus of $127.21 which suggests that it could grow by 4.78%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Ligand Pharmaceuticals, Inc. has a beta of 1.207, which suggesting that the stock is 20.687% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.269, suggesting its less volatile than the S&P 500 by 73.077%.

Ligand Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.7% to investors and pays a quarterly dividend of $0.85 per share. Ligand Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ligand Pharmaceuticals, Inc. quarterly revenues are $59.7M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Ligand Pharmaceuticals, Inc.'s net income of $44.8M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Ligand Pharmaceuticals, Inc.'s price-to-earnings ratio is 34.71x while Merck & Co., Inc.'s PE ratio is 16.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals, Inc. is 15.28x versus 4.69x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.